Sarah Gilbert

Last updated

Dame
Sarah Gilbert
DBE FRS
Dr.Sarah Gilbert.jpg
BornApril 1962 (age 62)
Kettering, Northamptonshire, England
Alma mater University of East Anglia (BSc)
University of Hull (PhD)
Known for Vaccinology
Children3
Awards Albert Medal (2021)
Princess of Asturias Award (2021)
King Faisal Prize (2023)
Scientific career
Fields Vaccines [1]
Institutions University of Oxford
Vaccitech
Delta Biotechnology
Leicester Biocentre
Brewing Industry Research Foundation
Christ Church, Oxford
Thesis Studies on lipid accumulation and genetics of Rhodosporidium toruloides  (1986)
Doctoral advisor Colin Ratledge, Dr M. Keenan
Website www.jenner.ac.uk/team/sarah-gilbert OOjs UI icon edit-ltr-progressive.svg

Dame Sarah Catherine Gilbert DBE FRS (born April 1962) is an English vaccinologist who is a Professor of Vaccinology at the University of Oxford and co-founder of Vaccitech. [2] [3] [4] [5] [6] She specialises in the development of vaccines against influenza and emerging viral pathogens. [7] She led the development and testing of the universal flu vaccine, which underwent clinical trials in 2011.

Contents

In January 2020, she read a report on ProMED-mail about four people in China suffering from a strange kind of pneumonia of unknown origin in Wuhan. [8] Within two weeks, a vaccine had been designed at Oxford against the new pathogen, which later became known as COVID-19. [9] On 30 December 2020, the Oxford–AstraZeneca COVID-19 vaccine she co-developed with the Oxford Vaccine Group was approved for use in the UK. [10] More than 3 billion doses of the vaccine were supplied to countries worldwide. [11]

Early life and education

Sarah Catherine Gilbert was born in Kettering, Northamptonshire. Her father was an office manager for a shoemakers and her mother was a primary school teacher. [12] Gilbert attended Kettering High School for Girls, where she realised that she wanted to work in medicine. [13] [14] She earned nine O-Levels with six A grades. [13] She graduated with a Bachelor of Science degree in biological sciences from the University of East Anglia (UEA) in 1983. [15] While at UEA she began playing the saxophone, which she would practise in the woods around the UEA Broad so as not to disturb others in her halls. [13] [16]

She moved to the University of Hull for her doctoral degree, where she investigated the genetics and biochemistry of the yeast Rhodosporidium toruloides , graduating with a PhD in 1986. [17] [14]

Research and career

After earning her doctoral degree, Gilbert worked as a postdoctoral researcher in industry at the Brewing Industry Research Foundation before moving to the Leicester Biocentre. In 1990, Gilbert joined Delta Biotechnology, a biopharmaceutical company that manufactured drugs in Nottingham. [14] [18] In 1994, Gilbert returned to academia, joining the laboratory of Adrian V. S. Hill. Her early research considered host–parasite interactions in malaria. She became a University lecturer in 1999 and she was made a Reader in Vaccinology at the University of Oxford in 2004. [14]

She was made Professor at the Jenner Institute in 2010. With the support of the Wellcome Trust, Gilbert started work on the design and creation of novel influenza vaccinations. [14] In particular, her research considers the development and preclinical testing of viral vaccinations, which embed a pathogenic protein inside a safe virus. [19] [20] These viral vaccinations induce a T cell response, which can be used against viral diseases, malaria and cancer. [19]

Graphical representation of the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), created by the Centers for Disease Control and Prevention, which reveals ultrastructural morphology exhibited by coronaviruses. SARS-CoV-2 without background.png
Graphical representation of the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), created by the Centers for Disease Control and Prevention, which reveals ultrastructural morphology exhibited by coronaviruses.

Gilbert was involved with the development and testing of the universal flu vaccine. Unlike conventional vaccinations, the universal flu vaccine did not stimulate the production of antibodies, but instead triggers the immune system to create T cells that are specific for influenza. [21] It makes use of one of the core proteins (nucleoprotein and matrix protein 1) inside the Influenza A virus, not the external proteins that exist on the outside coat. [22]

As the immune system weakens with age, conventional vaccinations are not effective for elderly. The universal flu vaccine does not need to be reformatted every year and stops people from needing a seasonal flu vaccine. Her first clinical trials, which were in 2008, made use of the Influenza A virus subtype H3N2, and included daily monitoring of the patient's symptoms. [22] [23] It was the first study that it was possible to stimulate T cells in response to a flu virus, and that this stimulation would protect people from getting the flu. [22] Her research has demonstrated that the adenoviral vector ChAdOx1 can be used to make vaccinations that are protective against Middle East respiratory syndrome (MERS) in mice and able to induce immune response against MERS in humans. [24] [25] The same vector was also used to create a vaccine against Nipah which was effective in hamsters (but never proven in humans), [26] in addition to a potential vaccine for Rift Valley Fever that was protective in sheep, goats, and cattle (but not proven in humans). [27]

Gilbert has been involved with the development of a new vaccination to protect against coronavirus since the beginning of the COVID-19 pandemic. [28] [29] [30] [2] She leads the work on this vaccine candidate alongside Andrew Pollard, Teresa Lambe, Sandy Douglas, Catherine Green and Adrian Hill. [31] As with her earlier work, the COVID-19 vaccine makes use of an adenoviral vector, which stimulates an immune response against the coronavirus spike protein. [28] [29] Plans were announced to start animal studies in March 2020, and recruitment began of 510 human participants for a phase I/II trial on 27 March. [32] [33] [34]

In April 2020, Gilbert was interviewed about the developments by Andrew Marr on BBC television. [35] That same month, Gilbert was reported as saying that her candidate vaccine could be available by September 2020, [36] if everything goes to plan with the clinical trial, which has received funding from sources such as the Coalition for Epidemic Preparedness Innovations. [37] Gilbert delivered an update in September 2020 that the vaccine, AZD1222, was being produced by AstraZeneca while phase III trials were ongoing. [38] Because of her vaccine research, Gilbert featured on The Times ' 'Science Power List' in May 2020. [39]

In 2021, Gilbert and Catherine Green published Vaxxers: the inside story of the Oxford AstraZeneca vaccine and the race against the virus. [40] [41]

Recognition

Gilbert was the subject of BBC Radio 4's The Life Scientific in September 2020. [42] She was also on the list of the BBC's 100 Women announced on 23 November 2020, [43] and became a senior associated research fellow at Christ Church, Oxford. [44] Gilbert was awarded the Rosalind Franklin medal for her services to science by Humanists UK at its annual Rosalind Franklin Lecture on 5 March 2021, [45] at which she delivered a lecture titled ‘Racing against the virus’. The lecture detailed the history of the science of vaccination and recounted the progress of the Oxford/AstraZeneca vaccine. [46]

In June 2021, Gilbert received a standing ovation at the 2021 Wimbledon Championships. [47] In 2021, as a role model (Barbie Shero), Sarah Gilbert had a Barbie doll made in her honour by the toy manufacturer Mattel. [48] [49]

Awards

Personal life

Gilbert gave birth to triplets in 1998. Her partner gave up his career to be their primary parent. [14] As of 2020, all of the triplets are studying biochemistry at university. [12]

Selected publications

Gilbert has an h-index of 105 according to Google Scholar. [1] Her publications include: [58] [59]

Related Research Articles

The Joint Committee on Vaccination and Immunisation (JCVI) is an independent expert advisory committee that advises United Kingdom health departments on immunisation, making recommendations concerning vaccination schedules and vaccine safety. It has a statutory role in England and Wales, and health departments in Scotland and Northern Ireland may choose to accept its advice.

Serum Institute of India (SII) is an Indian multinational biotechnology and biopharmaceuticals company, based in Pune. It is the world's largest manufacturer of vaccines by volume. It was founded by Cyrus Poonawalla in 1966 and is a part of Cyrus Poonawalla Group.

<span class="mw-page-title-main">Oxford Vaccine Group</span> Research group of the University of Oxford

The Oxford Vaccine Group (OVG) is a vaccine research group within the Department of Paediatrics at the University of Oxford. It was founded in 1994 by Professor E. Richard Moxon, was initially based at the John Radcliffe Hospital, and moved in 2003 to its current location in the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) at the Churchill Hospital in Oxford, England. The group, led by Professor Andrew Pollard since 2001, comprises around 75 members across a number of disciplines, including consultants in paediatrics and vaccinology, clinical research fellows, research nurses, statisticians, post-doctoral laboratory scientists, research assistants and DPhil students.

Sir Adrian Vivian Sinton Hill, is a British-Irish vaccinologist who is Director of the Jenner Institute and Lakshmi Mittal and Family Professor of Vaccinology at the University of Oxford, an honorary Consultant Physician in Infectious Diseases, and Fellow of Magdalen College, Oxford. Hill is a leader in the field of malaria vaccine development and was a co-leader of the research team which produced the Oxford–AstraZeneca COVID-19 vaccine, along with Professor Sarah Gilbert of the Jenner Institute and Professor Andrew Pollard of the Oxford Vaccine Group.

<span class="mw-page-title-main">COVID-19 pandemic in Panama</span>

The COVID-19 pandemic in Panama was a part of the worldwide pandemic of the coronavirus disease caused by severe acute respiratory syndrome coronavirus 2. The virus was confirmed to have spread to Panama on 9 March 2020. One of the dead was a 64-year-old male, who also had diabetes and pneumonia. Of those infected, 83 were hospitalized. The infected individuals belonged to the 29-59 age group and had each recently travelled abroad. A 13-year-old girl died of COVID-19 on 23 March 2020.

<span class="mw-page-title-main">Jenner Institute</span> Vaccine research institute in Oxford

The Jenner Institute is a research institute on the Old Road Campus in Headington, east Oxford, England. It was formed in November 2005 through a partnership between the University of Oxford and the UK Institute for Animal Health. It is associated with the Nuffield Department of Medicine, in the Medical Sciences Division of Oxford University. The institute receives charitable support from the Jenner Vaccine Foundation.

Catherine Mary Green is an English biologist who is an Associate Professor in Chromosome Dynamics at the Wellcome Centre for Human Genetics at the University of Oxford. Her research considers chromosome stability during the replication of DNA. During the COVID-19 pandemic Green was part of the Oxford team who developed the Oxford–AstraZeneca COVID-19 vaccine.

<span class="mw-page-title-main">Oxford–AstraZeneca COVID-19 vaccine</span> Viral vector vaccine for prevention of COVID-19

The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant and 61% against the Delta variant.

<span class="mw-page-title-main">Vaccine Taskforce</span> Non-departmental body coordinating efforts to introduce a COVID-19 vaccine

The Vaccine Taskforce in the United Kingdom of Great Britain and Northern Ireland was set up in April 2020 by the Second Johnson ministry, in collaboration with Chief Scientific Advisor Patrick Vallance and Chief Medical Officer Professor Chris Whitty, in order to facilitate the path towards the introduction of a COVID-19 vaccine in the UK and its global distribution. The taskforce coordinated the research efforts of government with industry, academics and funding agencies in order to expedite vaccine development and deployment.

ChAdOx1 is an adenoviral vector for vaccines that was developed by the Jenner Institute, University of Oxford. The vector is a chimpanzee adenovirus modified to avoid its replication.

<span class="mw-page-title-main">COVID-19 vaccination in the United Kingdom</span> Immunisation against COVID-19

The COVID-19 vaccination programme in the United Kingdom is an ongoing mass immunisation campaign for coronavirus disease 2019 (COVID-19) during the COVID-19 pandemic in the United Kingdom.

<span class="mw-page-title-main">Shabir Madhi</span> South African physician and professor

Shabir Ahmed Madhi, is a South African physician who is professor of vaccinology and director of the South African Medical Research Council Respiratory and Meningeal Pathogens Research Unit at the University of the Witwatersrand, and National Research Foundation/Department of Science and Technology Research Chair in Vaccine Preventable Diseases. In January 2021, he was appointed Dean of the Faculty of Health Sciences at the University of the Witwatersrand.

<span class="mw-page-title-main">History of COVID-19 vaccine development</span> Scientific work to develop a vaccine for COVID-19

SARS-CoV-2, the virus that causes COVID-19, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten the development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.

<span class="mw-page-title-main">COVID-19 vaccination in Australia</span> Ongoing COVID-19 vaccine program in Australia

The general COVID-19 vaccination in Australia program began on 22 February 2021 in response to the COVID-19 pandemic, with the goal of vaccinating all willing people in Australia before 2022. Front-line workers and aged care staff and residents had priority for being inoculated, before a gradual phased release to less-vulnerable and lower-risk population groups throughout 2021. The Therapeutic Goods Administration (TGA) approved four vaccines for Australian use in 2021: the Pfizer–BioNTech vaccine on 25 January, the Oxford–AstraZeneca vaccine on 16 February, Janssen vaccine on 25 June and the Moderna vaccine on 9 August. Although approved for use, the Janssen vaccine was not included in the Australian vaccination program as of June 2021.

<span class="mw-page-title-main">European Commission–AstraZeneca COVID-19 vaccine dispute</span> Dispute between the European Union and AstraZeneca

A dispute broke out in January 2021 between the European Commission and the pharmaceutical company AstraZeneca AB about the provision of COVID-19 vaccines during the COVID-19 pandemic, and, in February, spilled out into a dispute over Article 16 of the Northern Ireland Protocol. Vaccination proceeded apace in the UK but more slowly in the EU, and by the end of March 2021, over 30% of the UK population had received at least one dose of vaccine compared to about 8% of the EU population. This was partly due to limited availability of the AstraZeneca vaccine in the EU. The World Health Organization and the European Medicines Agency continued to state that the vaccine was safe and effective. However, a representative of the European Medicines Agency said in June that vaccines based on the mRNA technology should be preferred if available for all age groups, including for the over 60s.

<span class="mw-page-title-main">COVID-19 vaccination in South Africa</span> Plan to immunize against COVID-19 in South Africa

COVID-19 vaccination in South Africa is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

<span class="mw-page-title-main">Embolic and thrombotic events after COVID-19 vaccination</span> Post vaccination adverse effects

Post-vaccination embolic and thrombotic events, termed vaccine-induced immune thrombotic thrombocytopenia (VITT), vaccine-induced prothrombotic immune thrombocytopenia (VIPIT), thrombosis with thrombocytopenia syndrome (TTS), vaccine-induced immune thrombocytopenia and thrombosis (VITT), or vaccine-associated thrombotic thrombocytopenia (VATT), are rare types of blood clotting syndromes that were initially observed in a number of people who had previously received the Oxford–AstraZeneca COVID‑19 vaccine (AZD1222) during the COVID‑19 pandemic. It was subsequently also described in the Janssen COVID‑19 vaccine, leading to the suspension of its use until its safety had been reassessed. On 5 May 2022 the FDA posted a bulletin limiting the use of the Janssen Vaccine to very specific cases due to further reassessment of the risks of TTS, although the FDA also stated in the same bulletin that the benefits of the vaccine outweigh the risks.

Nita K. Patel is an Indian-American vaccinologist who leads vaccine development at Novavax. She oversaw the development of the Novavax COVID-19 vaccine.

<span class="mw-page-title-main">Susanna Dunachie</span> British microbiologist

Susanna Jane Dunachie is a British microbiologist who is Professor of Infectious Diseases at the University of Oxford. Her work considers microbiology and immunology to better understand bacterial infection and accelerate the development of vaccines. She has focused on melioidosis, scrub typhus and tuberculosis. During the COVID-19 pandemic, she studied T cell immunity to severe acute respiratory syndrome coronavirus 2.

References

  1. 1 2 Sarah Gilbert publications indexed by Google Scholar OOjs UI icon edit-ltr-progressive.svg
  2. 1 2 Richard Lane (1 April 2020). "Sarah Gilbert: carving a path towards a COVID-19 vaccine". The Lancet . 395 (10232): 1247. doi:10.1016/S0140-6736(20)30796-0. ISSN   0140-6736. PMC   7162644 . PMID   32305089. Wikidata   Q92035270.
  3. ↑ "Sarah Gilbert – Nuffield Department of Medicine". University of Oxford. Retrieved 10 February 2020.
  4. ↑ "Professor Sarah Gilbert". University of Oxford. Archived from the original on 2 July 2020. Retrieved 10 February 2020.
  5. ↑ "Professor Sarah Gilbert | University of Oxford". University of Oxford. Archived from the original on 3 August 2020. Retrieved 10 February 2020.
  6. ↑ "Our Team". vaccitech.co.uk. Retrieved 28 March 2020.
  7. ↑ "Professor Sarah Gilbert | Hic Vac". hic-vac.org.
  8. ↑ Gilbert, Sarah; Green, Catherine (2021). Vaxxers : the inside story of the Oxford vaccine and the race against the virus. London. ISBN   978-1529369854.{{cite book}}: CS1 maint: location missing publisher (link)
  9. ↑ McKie, Robin (4 July 2021). "Centre Court ovations, limbo-dancing grans – it's all been humbling, say Oxford vaccine creators". The Guardian . Retrieved 9 July 2021.
  10. ↑ "Covid-19: Oxford-AstraZeneca coronavirus vaccine approved for use in UK". BBC News. BBC. 30 December 2020. Retrieved 30 December 2020.
  11. ↑ "AstraZeneca withdraws Covid-19 vaccine, citing low demand". CNN . Retrieved 9 May 2024.
  12. 1 2 Cookson, Clive (24 July 2020). "Sarah Gilbert, the researcher leading the race to a Covid-19 vaccine". Financial Times . Retrieved 25 June 2021.
  13. 1 2 3 "Coronavirus vaccine: Who is Professor Sarah Gilbert?". Newsround . 24 November 2020. Retrieved 28 June 2021.
  14. 1 2 3 4 5 6 Admin. "Professor Sarah Gilbert". Working for NDM. Archived from the original on 27 March 2020. Retrieved 27 March 2020.
  15. ↑ "The UEA graduate leading hunt for coronavirus vaccine". Eastern Daily Press . 23 April 2020. Retrieved 20 June 2021.
  16. ↑ "UEA alumni in 2020". University of East Anglia . Retrieved 28 June 2021.
  17. ↑ Gilbert, Sarah Catherine (1986). Studies on lipid accumulaltion and genetics of Rhodosporidium toruloides. jisc.ac.uk (PhD thesis). University of Hull. OCLC   499901226. EThOS   uk.bl.ethos.381881.
  18. ↑ "Vaccine matters: Can we cure coronavirus?". Science Magazine. 12 August 2020. Retrieved 7 September 2020.
  19. 1 2 "Sarah Gilbert: Viral Vectored Vaccines — Nuffield Department of Medicine". University of Oxford. Retrieved 27 March 2020.
  20. ↑ "Professor Sarah Gilbert | Hic Vac". hic-vac.org. Retrieved 27 March 2020.
  21. ↑ "World-First Trial for Universal Flu Vaccine". Splice. 11 October 2017. Retrieved 27 March 2020.
  22. 1 2 3 Jha, Alok (6 February 2011). "Flu breakthrough promises a vaccine to kill all strains". The Guardian. ISSN   0261-3077 . Retrieved 27 March 2020.
  23. ↑ "Sarah Gilbert — The Jenner Institute". jenner.ac.uk. Retrieved 27 March 2020.
  24. ↑ Vincent J Munster; Daniel Wells; Teresa Lambe; et al. (16 October 2017). "Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model". NPJ Vaccines. 2: 28. doi:10.1038/S41541-017-0029-1. ISSN   2059-0105. PMC   5643297 . PMID   29263883. Wikidata   Q47147430.
  25. ↑ "New MERS Coronavirus vaccine clinical trial starts in Saudi Arabia". www.vaccitech.co.uk. 20 December 2019. Retrieved 22 March 2021.
  26. ↑ Neeltje van Doremalen; Teresa Lambe; Sarah Sebastian; et al. (6 June 2019). "A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters". PLoS Neglected Tropical Diseases . 13 (6): e0007462. doi: 10.1371/JOURNAL.PNTD.0007462 . ISSN   1935-2735. PMC   6581282 . PMID   31170144. Wikidata   Q64917294.
  27. ↑ George M Warimwe; Joseph Gesharisha; B Veronica Carr; et al. (5 February 2016). "Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever". Scientific Reports . 6: 20617. Bibcode:2016NatSR...620617W. doi:10.1038/SREP20617. ISSN   2045-2322. PMC   4742904 . PMID   26847478. Wikidata   Q36548980.
  28. 1 2 "Two groups of UK scientists in race to develop coronavirus vaccine". London Evening Standard. 7 February 2020. Retrieved 27 March 2020.
  29. 1 2 "Vaccine trials among recipients of £20 million coronavirus research investment". Government of the United Kingdom. Retrieved 27 March 2020.
  30. ↑ "Oxford team to begin novel coronavirus vaccine research | University of Oxford". University of Oxford. 7 February 2020. Retrieved 27 March 2020.
  31. ↑ "COVID-19 Vaccine Trials | COVID-19". covid19vaccinetrial.co.uk. Retrieved 11 April 2020.
  32. ↑ Sample, Ian (19 March 2020). "Trials to begin on Covid-19 vaccine in UK next month". The Guardian . ISSN   0261-3077 . Retrieved 27 March 2020.
  33. ↑ Robson, Steve (20 March 2020). "British scientists hope to start coronavirus vaccine trials next month". manchestereveningnews.co.uk. Retrieved 27 March 2020.
  34. ↑ "UK scientists enrol volunteers for coronavirus vaccine trial". The Guardian. 17 March 2020.
  35. ↑ "Prof Sarah Gilbert: Coronavirus vaccine trials to start within days". The Andrew Marr Show . UK. 19 April 2020. Retrieved 19 April 2020.
  36. ↑ hermesauto (11 April 2020). "Coronavirus vaccine could be ready in six months, says UK scientist". The Straits Times. Retrieved 11 April 2020.
  37. ↑ Stephanie Baker (30 March 2020). "How Top Scientists Are Racing to Beat the Coronavirus". Bloomberg News . Retrieved 11 April 2020.
  38. ↑ Lovett, Samuel (1 September 2020). "'You just get on with it': The Oxford professor carrying the world's hopes of a coronavirus vaccine". The Independent. Retrieved 8 September 2020.
  39. ↑ Franklin-Wallis, Oliver (23 May 2020). "From pandemics to cancer: the science power list". The Times. ISSN   0140-0460 . Retrieved 26 May 2020.
  40. ↑ Honigsbaum, Mark (11 July 2021). "Vaxxers by Sarah Gilbert and Catherine Green; Until Proven Safe by Geoff Manaugh and Nicola Twilley – reviews". The Guardian. Retrieved 12 June 2022.
  41. ↑ Ledford, Heidi (5 August 2021). "The COVID vaccine makers tell all". Nature. 596 (7870): 29–30. Bibcode:2021Natur.596...29L. doi:10.1038/d41586-021-02090-9. S2CID   236883504.
  42. ↑ Presenter: Jim Al-Khalili; Producer: Anna Buckley (15 September 2020). "Sarah Gilbert on developing a vaccine for Covid-19". The Life Scientific . BBC. BBC Radio 4 . Retrieved 15 September 2020.
  43. ↑ "BBC 100 Women 2020: Who is on the list this year?". BBC News. 23 November 2020. Retrieved 23 November 2020.
  44. ↑ "e-Matters 25th February 2021". www.chch.ox.ac.uk. Retrieved 9 September 2021.
  45. ↑ Gilbert, Sarah (2021). "Racing against the virus". The Rosalind Franklin Lecture. YouTube. Retrieved 7 December 2021.
  46. 1 2 "Vaccine creator Professor Sarah Gilbert delivers Rosalind Franklin Lecture to thousands". Humanists UK. Retrieved 8 March 2021.
  47. ↑ Duncan, Conrad (28 June 2021). "Wimbledon crowd gives standing ovation to Oxford Covid vaccine developer". The Independent. Retrieved 29 June 2021.
  48. ↑ "Vaccinologist Barbie: Prof Sarah Gilbert honoured with a doll". the Guardian. 4 August 2021.
  49. ↑ Ross, Deborah (24 May 2023). "Your Sarah Gilbert doll isn't realistic, Mattel. I want a Pay Gap Barbie" – via www.thetimes.co.uk.
  50. ↑ Oxford vaccine creator Professor Sarah Gilbert awarded RSA Albert Medal www.ox.ac.uk, Accessed 23 March 2021
  51. ↑ "No. 63377". The London Gazette (Supplement). 12 June 2021. p. B8.
  52. ↑ IT, Developed with webControl CMS by Intermark. "Katalin Karikó, Drew Weissman, Philip Felgner, Uğur Şahin, Özlem Türeci, Derrick Rossi and Sarah Gilbert - Laureates - Princess of Asturias Awards". The Princess of Asturias Foundation.
  53. ↑ "Royal Society of Medicine welcomes new Honorary Fellows and medal winners". Royal Society of Medicine . 28 July 2021. Retrieved 30 August 2021.
  54. ↑ "Covid vaccine co-creator Sarah Gilbert among 2022 UEA honorary graduates". Eastern Daily Press . 20 August 2021. Retrieved 30 August 2021.
  55. ↑ "Covid vaccine pioneer Dame Professor Sarah Gilbert receives honorary degree". www.bath.ac.uk. Retrieved 26 June 2024.
  56. ↑ King Faisal Prize 2023
  57. ↑ "Sarah Gilbert". royalsociety.org. Retrieved 14 May 2023.
  58. ↑ Sarah Gilbert publications from Europe PubMed Central
  59. ↑ Publications by Sarah Gilbert at ResearchGate OOjs UI icon edit-ltr-progressive.svg
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.